Abstract
DQ-2556 is a recently developed cephalosporin with a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria. Its in vitro activity was roughly comparable to those of cefuzonam and cefpirome and greater than those of ceftazidime, cefepime, and cefclidin against gram-positive bacteria. Against gram-negative bacteria, DQ-2556 showed almost the same activity as those shown by cefpirome and cefepime. The activity was largely unaffected by culture medium pH or the addition of human serum. The protective effect of DQ-2556 in experimental gram-positive pathogen and Escherichia coli infections in mice was greater than those of ceftazidime, cefuzonam, cefepime, and cefclidin and was similar to that of cefpirome. Against Pseudomonas aeruginosa and Acinetobacter calcoaceticus infections, DQ-2556 was more active than cefuzonam and had activity similar to or less than those of ceftazidime, cefpirome, cefepime, and cefclidin. When cells of E. coli were exposed to various concentrations of DQ-2556, filamentous cells were observed at concentrations of 0.0008 micrograms/ml and greater, spheroplasts started to form at 0.025 micrograms/ml, and subsequent cell lysis was observed. The affinity of DQ-2556 to PBP 3 of E. coli, which participates in septum formation, as suggested by morphological observation, was two times greater than that of ceftazidime. DQ-2556 also had high affinities for PBPs 1B and 1A of E. coli. These results suggest that DQ-2556 is worthy for subsequent clinical trials.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fujimoto T., Otani T., Nakajima R., Une T., Osada Y. In vitro activity of DQ-2556, a new cephalosporin. Antimicrob Agents Chemother. 1986 Oct;30(4):611–613. doi: 10.1128/aac.30.4.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fujimoto T., Watanabe M., Inoue M., Mitsuhashi S. In-vitro antibacterial activity of DQ-2556 and its stability to various beta-lactamases. J Antimicrob Chemother. 1990 Sep;26(3):329–341. doi: 10.1093/jac/26.3.329. [DOI] [PubMed] [Google Scholar]
- Hikida M., Inoue M., Mitsuhashi S. In-vitro antibacterial activity of L-105, a new cephalosporin. J Antimicrob Chemother. 1986 Nov;18(5):585–591. doi: 10.1093/jac/18.5.585. [DOI] [PubMed] [Google Scholar]
- Hiraoka M., Masuyoshi S., Mitsuhashi S., Tomatsu K., Inoue M. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime. J Antibiot (Tokyo) 1988 Jan;41(1):86–93. doi: 10.7164/antibiotics.41.86. [DOI] [PubMed] [Google Scholar]
- Inoue E., Mitsuhashi S. Interaction of E1040 with cephalosporinase from Citrobacter freundii GN7391. Antimicrob Agents Chemother. 1989 Dec;33(12):2157–2159. doi: 10.1128/aac.33.12.2157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Thornsberry C., Barry A. L. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984 Jun;25(6):710–718. doi: 10.1128/aac.25.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsubayashi K., Shintani S., Yoshioka M., Tachizawa H. Metabolic disposition of DQ-2556, a new cephalosporin, in rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1992 May;36(5):966–972. doi: 10.1128/aac.36.5.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Aswapokee N., Aswapokee P., Fu K. P. HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1979 Feb;15(2):273–281. doi: 10.1128/aac.15.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Chin N. X., Novelli A. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1988 Nov;32(11):1666–1675. doi: 10.1128/aac.32.11.1666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pucci M. J., Boice-Sowek J., Kessler R. E., Dougherty T. J. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312–2317. doi: 10.1128/aac.35.11.2312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanders C. C., Sanders W. E., Jr Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. J Infect Dis. 1985 Mar;151(3):399–406. doi: 10.1093/infdis/151.3.399. [DOI] [PubMed] [Google Scholar]
- Spratt B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2999–3003. doi: 10.1073/pnas.72.8.2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spratt B. G. Properties of the penicillin-binding proteins of Escherichia coli K12,. Eur J Biochem. 1977 Jan;72(2):341–352. doi: 10.1111/j.1432-1033.1977.tb11258.x. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Bedford K. A. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother. 1980 May;17(5):884–889. doi: 10.1128/aac.17.5.884. [DOI] [PMC free article] [PubMed] [Google Scholar]